Breaking News

Mexico becomes the first country of North America to register Sputnik V vaccine

Moscow, February 3, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the registration of the Russian Sputnik V vaccine against coronavirus by the Federal Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS).

The vaccine was approved under the emergency use authorization procedure without additional clinical trials in the country. Mexico has become the first country of North America to approve Sputnik V and the 17th country in the world.

Sputnik V had been approved earlier in Russia, Belarus, Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay, Turkmenistan, Hungary, UAE, Iran, Republic of Guinea, Tunisia and Armenia.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:

“We welcome the decision of regulatory authorities of Mexico to register Sputnik V vaccine and include it in the national portfolio of vaccines against coronavirus. Partnership between Russia and Mexico will save many lives and protect the population by using one of the best vaccines in the world. High efficacy of Sputnik V was confirmed yesterday by data published in one of the most respected medical journals The Lancet”.

 

Sputnik V has a number of key advantages:

  • Efficacy of Sputnik V is 91.6% as confirmed by the data published in the Lancet, one of the world’s oldest and most respected medical journals; Sputnik V provides full protection against severe cases of COVID-19.
  • The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
  • Sputnik V uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
  • The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
  • The developers of the Sputnik V vaccine are working collaboratively with AstraZeneca on a joint clinical trial to improve the efficacy of AstraZeneca vaccine.
  • There are no strong allergies caused by Sputnik V.
  • The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
  • The price of Sputnik V is less than $10 per shot, making it affordable around the world.

About Admin

newspatrolling

Comments are closed.

Scroll To Top